Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Danco Revises Mifeprex Labeling To Add Post-Marketing Adverse Reactions

This article was originally published in The Pink Sheet Daily

Executive Summary

Adverse events for the abortifacient include allergic reactions, hypotension, light-headedness, shortness of breath and tachycardia. Reports of serious infections and ruptured ectopic pregnancies prompted FDA to strengthen Mifeprex’ “black box” warning in November.
Advertisement

Related Content

Mifeprex “Black Box” Warning Revised On Reports Of Sepsis Deaths
Mifeprex “Black Box” Warning Revised On Reports Of Sepsis Deaths
Mifeprex Label Will Add Further Language On Infection Risk
Mifeprex Label Will Add Further Language On Infection Risk
Mifeprex Labeling Change Not A Move Toward Product Withdrawal, FDA Says
FDA Revises Mifeprex “Black Box” To Warn About Infection, Bleeding
FDA Revises Mifeprex “Black Box” To Warn About Infection, Bleeding

Topics

Advertisement
UsernamePublicRestriction

Register

PS061046

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel